BioSpace News Archive

Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022.

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President, Business Development.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will present a corporate overview at the H.C. Wainwright BIOCONNECT Conference, held virtually January 10-13, 2022.

Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.

Algernon Pharmaceuticals Inc. reports that the Company has granted 96,000 stock options exercisable at $4.10 for five years from date of grant, for officers and directors, employees and a consultant and are subject to approval by regulatory authorities.

Cumberland Pharmaceuticals Inc. announced today that it has entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), from Kyowa Kirin, Inc.

Lantern Pharma (NASDAQ: LTRN), today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares.

Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest.